You are here: Home / GW Innovations / Technologies Available

Intranasal Oxytocin Therapy for Obstructive Sleep Apnea

Technology #015-001-mendelowitz

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Image Gallery
Activating oxytocin-releasing neurons prevents increase in blood pressure during chronic intermittent low oxygen in rats.Percent Hypopneas with Arousals in Sleep Apnea Patients significantly decreased with Oxytocin
David Mendelowitz
External Link (
Vivek Jain
Heather Jameson
Jay Shawn Kimbro
Managed By
Brian Coblitz
Sr. Licensing Associate (202) 994-4345
Patent Protection

Oxytocin Improves Treatment of Obstructive Sleep Apnea

US Patent Pending 2017-0143790
Benefits of oxytocin administration in obstructive sleep apnea
Am J Physiol Lung Cell Mol Physiol, 313: L825-L833 (2017)
Chronic intermittent hypoxia–hypercapnia blunts heart rate responses and alters neurotransmission to cardiac vagal neurons
J Physiol, 592.13 (2014)

Obstructive sleep apnea (OSA) is a health risk that occurs in 24% of males and 9% of females in the United States. OSA can lead to several cardiovascular diseases including hypertension, arrhythmia, and stroke. Continuous positive airway pressure (CPAP) treatments often fail due to low compliance.

GW Researchers developed an intranasal oxytocin administration method that protects OSA patients by maintaining cardiovascular homeostasis. They also see potential for decreasing awakening events, increasing sleep quality, and increasing compliance with CPAP.

Oxytocin is a human peptide hormone well known for its roles in childbirth. Oxytocin is also involved in anxiety and social bonding, which is why it may help with CPAP compliance. In animal models of social stressors, oxytocin has been shown to be protective against behavioral and cardiac dysfunction. 

Human sleep studies are underway at GW. Cardiac benefits of stimulating oxytocin-releasing neurons in the brain were seen when in rats faced with chronic intermittent low oxygen (a model for OSA).


  • Treat OSA patients with or without concurrent CPAP


  • Reduce risk of cardiovascular diseases such as hypertension and tachycardia
  • Increase Patient compliance with standard CPAP treatment
  • Can integrate with CPAP device for intranasal delivery by nebulizer